<p>Your are about to enter the global website of the B. Braun Group. We recommend you visit the website of your local B. Braun organization.</p>

United States - B. Braun Medical Inc.

<p>Not all products are registered and approved for sale in all countries or regions. Indications of use also may vary by country and region. Please contact your country representative for product availability and information. Product images are for reference only.</p>

Cancel

You have successfully logged out.

SeQuent® DCBs

Your way to confidence

Enter the world of SeQuent^® DCB treatment with cutting-edge balloon technology and a proven leader at your side – for more drug options, more clinical data, high-quality support and the confidence you’re aiming for.

Cardiovascular News

New Momentum in DCB-PCI - Insights from B. Braun DCB Day

At the recent DCB Days nine esteemed DCB experts like Raban Jeger and Robert Byrne shared their key concepts and insights on the principle of leaving nothing behind in coronary vessels. The course covered key concepts and practical applications, allowing attendees to deepen their understanding and enhance their skills in this area.

Read article

Paclitaxel coated balloon

SeQuent® Please NEO – Master of evidence

The SeQuent® Please NEO is a drug coated balloon catheter for treating stenosis of coronary arteries with PTCA, while leaving nothing behind. The PCB has a matrix coating (PACCOCATH®-Technology), which helps to keep coronary arteries open by inhibiting smooth muscle cell proliferation and migration.

B. Braun´s paclitaxel coated balloon SeQuent® Please NEO is the best investigated DCB [1] in the field of percutaneous coronary interventions (PCI). It has demonstrated its convincing performance, efficacy and safety in more than 110 published studies (including more than 35 RCTs) – with over 25,000 documented patients, conducted in more than 20 countries.

SeQuent® Please NEO – Paclitaxel coated balloon

> 0

published studies
> 0

documented patients
> 0

countries

Publications for SeQuent® Please / NEO

The coronary DCB has been investigated in more than 110 studies with over 25,000 documented patients, conducted in more than 20 countries.

Download studies now

Sirolimus coated balloon

SeQuent® SCB – Pioneer of proof

B. Braun´s new sirolimus coated balloon is the first SCB backed up with published randomized clinical trials for ISR and de-novo lesions.^{[2], [3], [4]}SeQuent® SCB now offers new implant-free options for treating coronary ISR and de-novo lesions, providing excellent results in targeted drug delivery and sirolimus persistence. The combination of sirolimus and BHT (Butylated Hydroxy Toluol) creates the desired crystalline sirolimus modification to reach best results regarding sirolimus vessel wall content compared to other excipients.^[5]

SeQuent® SCB is the only coronary sirolimus coated balloon with published RCTs: 2 RCTs on ISR lesions, 1 RCT on de-novo lesions
Multicenter data from Europe and Asia
Ongoing studies for de-novo and real world

How and when should I best use DCBs

Watch the expert videos

DCB may be an appealing strategy in diabetic patients

"The prognosis for diabetic patients can be worse when using drug-eluting stents. The use of drug coated ballons may be the better choice for diatebic patients."

„How using DCBs can „open up a new world“ for PCI

Early exposure to the use of drug-coated balloons (DCBs) for percutaneous coronary intervention (PCI) “opened my eyes to a whole new world of angioplasty without putting stents in.”

“DCBs and stents are complementary devices and not the opposite.”

What role do DCBs play in the modern interventional cardiology toolbox? Dr. Victor Jimenez takes on this and other questions from Cardiovascular News.

Ready for primetime? The future role of drug-coated balloons in PCI

Dr. Marie-Claude Morice (Institute Hospitalier Jacques Cartier, Massy, France) discusses the future role of DCBs in coronary interventions.

Important to utilise DCBs with strongest possible data

Dr. Tuomas Rissanen (North Karelia Central Hospital, Joensuu, Finland) speaks to Cardiovascular News about the benefits of using a drug coated balloon, the clinical indications and more.

DCB and the good night sleep

Bruno Scheller, Raban Jeger and Tuomas Rissanen talk about their experiences with DCBs and why there is no need to fear acute vessel closures.

DCB may be an appealing strategy in diabetic patients
„How using DCBs can „open up a new world“ for PCI
“DCBs and stents are complementary devices and not the opposite.”
Ready for primetime? The future role of drug-coated balloons in PCI
Important to utilise DCBs with strongest possible data
DCB and the good night sleep

Study summaries SeQuent® Please / NEO

Randomized controlled trials

2020 | Primary Investigator: Jeger R | Study Aim: SQP vs. DES, Vessel: RD ≤ 3 mm | (Primary) Endpoint: MACE @ 36-month follow-up | Patients: 758

Summary BASKET-SMALL 2

2017 | Primary Investigator: Funatsu A | Study Aim: DCB vs. POBA, Vessel: RD ≤ 2.75 mm, ≥ 2 mm | (Primary) Endpoint: TVF @ 6-month follow-up | Patients: 135

Summary PEPCAD Japan SVD

2017 | Primary Investigator: Gobić D | Study Aim: DCB vs. DES, Patients: STEMI (< 12 h) | (Primary) Endpoint: MACE, LLL @ 6-month follow-up | Patients: 75

Summary AMI Feasibility Study

2016 | Primary Investigator: Nishiyama N | Study Aim: DCB vs. DES | (Primary) Endpoint: TLR @ 8-month follow-up | Patients: 60

Summary Clinical Value "Stent-less" PCI

Not randomized controlled trials & observational studies

2019 | Primary Investigator: Rosenberg M | Study Aim: DCB – ISR & De Novo | (Primary) Endpoint: TLR @ 9-month follow-up | Patients: 1,025

Summary DCB-only All-Comers Registry

2016 | Primary Investigator: Shin E | Study Aim: DCB – De Novo, Vessel: RD ≤ 3.5 mm, ≥ 2.5 mm | (Primary) Endpoint: LLL, FFR @ 9-month follow-up, MI, TLR @ 12-month follow-up | Patients: 67

Summary FFR-Guided DCB-Angioplasty

2014 | Primary Investigator: Zeymer U | Study Aim: DCB – De Novo, Vessel: RD ≤ 2.75 mm, ≥ 2.0 mm | (Primary) Endpoint: TLR @ 9-month follow-up | Patients: 447

Summary SVD Registry

2023 | Primary Investigator: Shin ES | Study Aim: Investigate the impact of DCB-based treatment on PCI for multivessel CAD | (Primary) Endpoint: MACE @ 24-months (cardiac death, MI, TVR, stroke, stent thrombosis and major bleeding) | Patients: 508

Summary DCB-based PCI in Multi-Vessel-Disease

Clinical evidence SeQuent® SCB

Preclinical work and randomized controlled trials

Sirolimus + BHT (Butylated Hydroxy Toluol): Persistence in the vessel wall

Two RCTs for SeQuent® SCB vs. SeQuent® Please NEO with angiographic and clinical follow-ups.

Read summary

RCT for SeQuent® SCB vs. SeQuent® Please NEO with angiographic and clinical follow-ups.

Read summary

Get in touch with our Coronary Drug Coated Balloon experts

References

All numbers referring to clinical coronary trials on PCBs, patients enrolled therein and countries in which these trials were conducted, are based on a PubMed literature search conducted with due diligence in February/March 2022. (Data on file at B. Braun)
Ali RM et al J Am Coll Cardiol Intv 2019;12:558-66
Scheller B et al. Circ Cardiovasc Interv. 2022 Sep;15(9):e012305.
Ahmad WAW et al. JACC Cardiovasc Interv. 2022 Apr 11;15(7):770-779
Clever et al. Circ Cardiovasc Interv. 2016 Apr;9(4):e003543.
Kleber FX et al. Clin Res Cardiol. 2013 Nov;102(11):785-97.
Jeger RV et JACC Cardiovasc Interv. 2020 Jun 22;13(12):1391-1402.

Your way to confidence

On this page

Cardiovascular News